At a glance
- Originator Pharmacia Corporation
- Class Anxiolytics
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 08 Jul 1998 No-Development-Reported for Anxiety disorders in USA (Unknown route)
- 15 Nov 1994 Preclinical development for Anxiety disorders in USA (Unknown route)